 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || human recombinant dHGF (CSB-001) / Claris Biotherap
Enrollment change: CSB-C23-001: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency (clinicaltrials.gov) - Feb 12, 2025
P1, N=65, Recruiting, Sponsor: Claris Biotherapeutics, Inc.
N=40 --> 65
- | human recombinant dHGF (CSB-001) / Claris Biotherap
Trial completion date, Trial primary completion date: CSB-C23-002: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars (clinicaltrials.gov) - Feb 11, 2025
P1, N=20, Recruiting, Sponsor: Claris Biotherapeutics, Inc.
N=40 --> 65 Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Dec 2024 --> May 2025
- || human recombinant dHGF (CSB-001) / Claris Biotherap
Enrollment change: CSB-C23-001: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency (clinicaltrials.gov) - Oct 2, 2024
P1, N=40, Recruiting, Sponsor: Claris Biotherapeutics, Inc.
Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Dec 2024 --> May 2025 N=20 --> 40
- ||| human recombinant dHGF (CSB-001) / Claris Biotherap
Trial completion: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (clinicaltrials.gov) - Aug 28, 2024
P1/2, N=131, Completed, Sponsor: Claris Biotherapeutics, Inc.
N=20 --> 40 Active, not recruiting --> Completed
- || human recombinant dHGF (CSB-001) / Claris Biotherap
Enrollment closed, Trial primary completion date: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (clinicaltrials.gov) - Jun 25, 2024
P1/2, N=128, Active, not recruiting, Sponsor: Claris Biotherapeutics, Inc.
Active, not recruiting --> Completed Trial primary completion date: Apr 2024 --> Jul 2024 | Recruiting --> Active, not recruiting
- || human recombinant dHGF (CSB-001) / Claris Biotherap
New P1 trial: CSB-C23-001: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency (clinicaltrials.gov) - Jun 11, 2024
P1, N=20, Recruiting, Sponsor: Claris Biotherapeutics, Inc.
- || human recombinant dHGF (CSB-001) / Claris Biotherap
New P1 trial: CSB-C23-002: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars (clinicaltrials.gov) - Feb 13, 2024
P1, N=20, Recruiting, Sponsor: Claris Biotherapeutics, Inc.
- || human recombinant dHGF (CSB-001) / Claris Biotherap
Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (clinicaltrials.gov) - Dec 20, 2023
P1/2, N=128, Recruiting, Sponsor: Claris Biotherapeutics, Inc.
Trial primary completion date: Apr 2024 --> Jul 2024 | Recruiting --> Active, not recruiting Trial completion date: Feb 2024 --> Jul 2024 | Trial primary completion date: Nov 2023 --> Apr 2024
- || human recombinant dHGF (CSB-001) / Claris Biotherap
Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (clinicaltrials.gov) - Nov 25, 2022
P1/2, N=108, Recruiting, Sponsor: Claris Biotherapeutics, Inc.
Trial completion date: Feb 2024 --> Jul 2024 | Trial primary completion date: Nov 2023 --> Apr 2024 Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Nov 2022 --> Nov 2023
- ||| human recombinant dHGF (CSB-001) / Claris Biotherap
Enrollment open: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (clinicaltrials.gov) - Jun 28, 2021
P1/2, N=108, Recruiting, Sponsor: Claris Biotherapeutics, Inc.
Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Nov 2022 --> Nov 2023 Not yet recruiting --> Recruiting
- | human recombinant dHGF (CSB-001) / Claris Biotherap
New P1/2 trial: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (clinicaltrials.gov) - Jun 1, 2021
P1/2, N=108, Not yet recruiting, Sponsor: Claris Biotherapeutics, Inc.